Risk III -excision line not certainly within healthy tissuemulticentral tumor focuses in the preparation -extended lymphangiosis -CLIS or CDIS extended to the resection llne
Risk IV -excision of tumor certainly not within healthy tissue.
Reviewing our cases, we found no local recurrence in group I, as expected, and an increase of the rate of recurrence according to the higher risk groups (III-IV). Furthermore there was no difference between patients with and without additional irradiation within each group. Group llI-patients seemed to have the best benefit by irradiation. As results have shown that the probability of local recurrence can be determined fairly certain thereby, we ore able to classify our patients in high risk groups (III+ IV) Background: Hyperprolactinaemia in breast cancer pts is associated with tumour load and progressive disease. Since elevated PRL levels return to normal when a remission is achieved in these pts, an ectopic production of prolactin by the tumour would be a possible explanation. Method: Prolactin stimulation and suppression tests and 24 h hormone profiles were performed on 34 pts with metastatic breast cancer associated with hyperprolactinaemia. In all pts uraemia, surgery or drugs were ruled out as causing the hyperprolaetinaemia. Stimulation of the prolactin release was performed with 200 mcg TRH iv by an indwelling catheter. 18 pts were given 10 mg bromocriptine (dopamine agenist) and 16 pts 12 mg metergoline (serotonine antagonist) p.o. to test the suppression of prolactin release by two different pathways. The prolactin levels were measured before and 20 min after TRH stimulation and 7-14 days after begin of bromocriptine or metergoline treatment. Prolactin was measured by radioimmunoassay (normal range 50 -500 mlU/1). Results-The mean basal prolactin level of the pts was 185 mlU/1. A sleep-related surge was observed in all pts. The prolactin release was stimulated by TRH (1785 +/-473 mlU/l) and suppressed by bromocriptine (80 +/-12 mlU/1) or metergoline (249 +/-46 mlU/l) in all pts. After withdrawal of bromocriptine or metergoline treatment, the prolactin levels returned to hyperprolactinaemic values. It is concluded that hyperprolactinaemia in breast cancer pts is not caused by an ectopic production of prolactin in turnout cells.
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